Workshop

Secondment at Bayer

Published April 06, 2023

  • Suraj Patil, ESR2, who is usually working at Universität Freiburg with Prof. Anna Köttgen, spent 2 months at Bayer to train with Dr. Frank Eitner and his teams. 

    Dr. Frank Eitner is VP and Head Kidney Diseases Research at Bayer. During his secondment Suraj also had the chance to work in the lab of Dr. Laura Luh, Dr. Jürgen Klar, and with several people from the LST, LIC and pre-Med departments at Bayer.

    You can have a look a Suraj thesis subject here.

    • What is a Secondment?

      A Secondment in Innovative Training Networks is mobility of the Early Stage Researcher to another member of the consortium (beneficary or partner organisation). It is an integral part of their research and training project. During their secondment, researchers receive supervision and training from a Principal Investigator in the host institution. During this period the researcher experiences her or his researcher under a new perspective. Inter-sectoral secondment are highly recommended. In TrainCKDis training programme, we did our best to organise the secondments from academic to non-academic sectors or the other way around.

    • Members of the TrainCKDis consortium

      TrainCKDis brings together 9 interdisciplinary academic research teams and non-academic teams, all internationally renowned for contributions to kidney research. This are the beneficiaries of the project that hire the Early Stage Researchers. You kind find the beneficiaries list here.

      The consortium also includes 6 partners, including private and public institution as well as a patient association. They are keys to the training of our students. The lists is hehttps://www.trainckdis.eu/consortium/partner-organisationsre.

      And last but not least, the heart of the consortium and the scientific project is the Early Stage Researchers, the PhD students that are working, enabling the consortium as a whole to meet the objectives we set.

  • During his time there, Suraj focused on advancing a target into the drug development pipeline by designing experiments, establishing reporter assays, and conducting cell and molecular biology experiments. The experience was truly enriching, and he had the opportunity to work alongside experts in various fields, who also provided invaluable guidance and helped him develop ideas for his PhD project.

  • "I'm thrilled to share that I recently completed a 2-month secondment at Bayer AG as part of my Early Stage Researcher Fellow Training in the TrainCKDis consortium.

    Through this internship, I was able to contribute to a drug development project, gain valuable insights into cutting-edge industry research, and further improve my PhD project. I'm excited to apply these learnings as I continue to grow in my academic and professional career. "